After the latest funding and merger, OnKure will have enough resources to support operations into Q4 2026, including development of its PI3Kα inhibitors.
The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.
The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.